Genmab A/S (GMAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genmab A/S (GMAB) has a cash flow conversion efficiency ratio of 0.093x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr536.00 Million ≈ $83.86 Million USD) by net assets (Dkr5.75 Billion ≈ $899.79 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Genmab A/S - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Genmab A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Genmab A/S balance sheet liabilities for a breakdown of total debt and financial obligations.
Genmab A/S Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genmab A/S ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bank Polska Kasa Opieki SA
WAR:PEO
|
0.245x |
|
Brookfield Infrastructure Partners L.P
TO:BIP-UN
|
0.058x |
|
Annaly Capital Management, Inc.
NYSE:NLY
|
0.040x |
|
Bank of Beijing Co Ltd
SHG:601169
|
-0.375x |
|
Telkom Indonesia (Persero) Tbk PT
JK:TLKM
|
0.110x |
|
Alamos Gold Inc
TO:AGI
|
0.064x |
|
PTC Inc
NASDAQ:PTC
|
0.070x |
|
Textron Inc
NYSE:TXT
|
0.089x |
Annual Cash Flow Conversion Efficiency for Genmab A/S (2002–2024)
The table below shows the annual cash flow conversion efficiency of Genmab A/S from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see Genmab A/S (GMAB) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Dkr36.70 Billion ≈ $5.74 Billion |
Dkr7.77 Billion ≈ $1.22 Billion |
0.212x | -9.30% |
| 2023-12-31 | Dkr31.61 Billion ≈ $4.95 Billion |
Dkr7.38 Billion ≈ $1.15 Billion |
0.233x | +62.82% |
| 2022-12-31 | Dkr27.28 Billion ≈ $4.27 Billion |
Dkr3.91 Billion ≈ $612.06 Million |
0.143x | +42.85% |
| 2021-12-31 | Dkr22.20 Billion ≈ $3.47 Billion |
Dkr2.23 Billion ≈ $348.59 Million |
0.100x | -70.16% |
| 2020-12-31 | Dkr19.12 Billion ≈ $2.99 Billion |
Dkr6.43 Billion ≈ $1.01 Billion |
0.336x | +256.43% |
| 2019-12-31 | Dkr14.05 Billion ≈ $2.20 Billion |
Dkr1.33 Billion ≈ $207.46 Million |
0.094x | -25.45% |
| 2018-12-31 | Dkr8.01 Billion ≈ $1.25 Billion |
Dkr1.01 Billion ≈ $158.77 Million |
0.127x | -50.02% |
| 2017-12-31 | Dkr6.27 Billion ≈ $981.33 Million |
Dkr1.59 Billion ≈ $248.61 Million |
0.253x | +273.12% |
| 2016-12-31 | Dkr4.83 Billion ≈ $755.17 Million |
Dkr327.72 Million ≈ $51.27 Million |
0.068x | -23.99% |
| 2015-12-31 | Dkr3.49 Billion ≈ $545.52 Million |
Dkr311.45 Million ≈ $48.73 Million |
0.089x | +36.87% |
| 2014-12-31 | Dkr2.03 Billion ≈ $318.07 Million |
Dkr132.67 Million ≈ $20.76 Million |
0.065x | +133.63% |
| 2013-12-31 | Dkr659.52 Million ≈ $103.19 Million |
Dkr-128.00 Million ≈ $-20.03 Million |
-0.194x | -204.86% |
| 2012-12-31 | Dkr383.19 Million ≈ $59.95 Million |
Dkr70.92 Million ≈ $11.10 Million |
0.185x | +120.59% |
| 2011-12-31 | Dkr486.42 Million ≈ $76.10 Million |
Dkr-437.23 Million ≈ $-68.41 Million |
-0.899x | -462.02% |
| 2010-12-31 | Dkr1.08 Billion ≈ $168.98 Million |
Dkr268.17 Million ≈ $41.96 Million |
0.248x | +156.50% |
| 2009-12-31 | Dkr1.30 Billion ≈ $202.96 Million |
Dkr-570.06 Million ≈ $-89.19 Million |
-0.439x | -87.36% |
| 2008-12-31 | Dkr2.19 Billion ≈ $342.42 Million |
Dkr-513.33 Million ≈ $-80.31 Million |
-0.235x | -233.68% |
| 2007-12-31 | Dkr2.88 Billion ≈ $451.11 Million |
Dkr505.90 Million ≈ $79.15 Million |
0.175x | +174.30% |
| 2006-12-31 | Dkr1.61 Billion ≈ $251.52 Million |
Dkr-379.62 Million ≈ $-59.39 Million |
-0.236x | -26.62% |
| 2005-12-31 | Dkr1.12 Billion ≈ $175.04 Million |
Dkr-208.64 Million ≈ $-32.64 Million |
-0.186x | +40.10% |
| 2004-12-31 | Dkr1.18 Billion ≈ $184.77 Million |
Dkr-367.70 Million ≈ $-57.53 Million |
-0.311x | -11.87% |
| 2003-12-31 | Dkr1.09 Billion ≈ $169.98 Million |
Dkr-302.36 Million ≈ $-47.31 Million |
-0.278x | -26.30% |
| 2002-12-31 | Dkr1.40 Billion ≈ $218.91 Million |
Dkr-308.32 Million ≈ $-48.24 Million |
-0.220x | -- |
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervic… Read more